Intellia is a publicly listed company tracked for investment-relevant business developments.
ARK Invest believes Intellia’s prospective cure for hereditary angioedema could command multi‑million‑dollar pricing, implying a $20‑30 billion market despite the stock’s recent decline on unrelated data.